Combining strategies in the counseling and care of the cataract patient

Combining strategies in the counseling and care of the cataract patient

This activity is sponsored by Bausch + Lomb.

Introduction

More than three million cataract surgeries are performed in the United States each year,1 and that number is expected to increase. The main objective for patients undergoing cataract surgery is to improve quality of vision. Cataract surgery causes inflammation; therefore, treatment of inflammation is important to the patient.

Ocular Surgery News, with the support of Bausch + Lomb, gathered a panel of leading ophthalmologists during Hawaiian Eye 2016 to discuss treating postoperative ocular pain and inflammation following ocular surgery using LOTEMAX® Gel (loteprednol etabonate ophthalmic gel) 0.5% (Bausch + Lomb) and treating postoperative pain and inflammation following cataract surgery using PROLENSA® (bromfenac ophthalmic solution) 0.07% (Bausch + Lomb). The panel also discussed methods and tips for counseling patients on obtaining and administering these medications.

I thank the expert panelists for their participation, as well as Bausch + Lomb for sponsoring this Ocular Surgery News supplement. For more educational materials on this topic, visit Healio.com/Ophthalmology/Education-Lab.

Richard L. Lindstrom, MD
Chief Medical Editor
Ocular Surgery News

Important Safety Information for Lotemax Gel

LOTEMAX® Gel (loteprednol etabonate ophthalmic gel) 0.5% is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.

Click here for full Prescribing information (PDF version) for Lotemax Gel.

Important Safety Information for Prolensa

PROLENSA® contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

The most commonly reported adverse reactions in 3% to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred.

Click here for full Prescribing information (PDF version) for Prolensa.


Additional Important Safety Information for both Prolensa and Lotemax Gel is provided via left navigation links.


References

1.    Harmon D. “Lenstec (Barbados) Inc. Sets Sights on U.S. Market.” Ophthalmic Market Perspectives (2010).

 

PRA.0050.USA.16

Introduction

page 1 of 7